Eyewire News: The Podcast
12.03.25
Eylea HD gains FDA approval for a new indication and dosing schedule; Lucentis biosimilar Byooviz receives a key approval in Europe; and Belite Bio announces topline results from its global phase 3 trial evaluating its drug candidate for Stargardt disease. Learn more about your ad choices. Visit megaphone.fm/adchoices
View full description +
Subscribe
11.18.25
Live Coverage of B+L Investor DayShow More